Cargando…

Putting the BRK on breast cancer: From molecular target to therapeutics

BReast tumor Kinase (BRK, also known as PTK6) is a non-receptor tyrosine kinase that is highly expressed in breast carcinomas while having low expression in the normal mammary gland, which hints at the oncogenic nature of this kinase in breast cancer. In the past twenty-six years since the discovery...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ang, Hui Li, Yuan, Yi, Lai, Xianning, Tan, Tuan Zea, Wang, Lingzhi, Huang, Benjamin BoJun, Pandey, Vijay, Huang, Ruby Yun-Ju, Lobie, Peter E., Goh, Boon Cher, Sethi, Gautam, Yap, Celestial T., Chan, Ching Wan, Lee, Soo Chin, Kumar, Alan Prem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738883/ https://www.ncbi.nlm.nih.gov/pubmed/33391524 http://dx.doi.org/10.7150/thno.49716

Ejemplares similares

Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective
por: Ong, Mei Shan, et al.
Publicado: (2020)

BrkAutoDisplay: functional display of multiple exogenous proteins on the surface of Escherichia coli by using BrkA autotransporter
por: Sun, Fang, et al.
Publicado: (2015)

Role of the Brk tyrosine kinase in breast cancer progression
por: Harvey, AJ, et al.
Publicado: (2006)

Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis
por: Datta, Arpita, et al.
Publicado: (2021)

Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
por: Lee, Matilda, et al.
Publicado: (2018)

Brk expression may affect the differentiation status of breast cancer cells
por: Harvey, AJ, et al.
Publicado: (2008)

Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer
por: Kansara, Samarth, et al.
Publicado: (2020)

Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers
por: Loo, Ser Yue, et al.
Publicado: (2021)

Gelsolin-Cu/ZnSOD interaction alters intracellular reactive oxygen species levels to promote cancer cell invasion
por: Tochhawng, Lalchhandami, et al.
Publicado: (2016)

The potential role of exosomal circRNAs in the tumor microenvironment: insights into cancer diagnosis and therapy
por: Li, Juan, et al.
Publicado: (2022)

High-Resolution X-Ray Structure of the Trimeric Scar/WAVE-Complex Precursor Brk1
por: Linkner, Joern, et al.
Publicado: (2011)

Breast tumor kinase (Brk/PTK6) plays a role in the differentiation of primary keratinocytes
por: Tupper, J., et al.
Publicado: (2011)

PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors
por: Peng, Maoyu, et al.
Publicado: (2014)

BRK Targets Dok1 for Ubiquitin-Mediated Proteasomal Degradation to Promote Cell Proliferation and Migration
por: Miah, Sayem, et al.
Publicado: (2014)

SPHK1 regulates proliferation and survival responses in triple-negative breast cancer
por: Datta, Arpita, et al.
Publicado: (2014)

A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma
por: Zhang, Mengyi, et al.
Publicado: (2019)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma
por: Liu, Xue-Kui, et al.
Publicado: (2013)

Correction: BRK Targets Dok1 for Ubiquitin-Mediated Proteasomal Degradation to Promote Cell Proliferation and Migration
Publicado: (2014)

A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs
por: Wong, Andrea Li-Ann, et al.
Publicado: (2018)

Brk/PTK6 and Involucrin Expression May Predict Breast Cancer Cell Responses to Vitamin D3
por: Box, Carol, et al.
Publicado: (2023)

Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK
por: Chen, Ru-Mei, et al.
Publicado: (2019)

A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study
por: Wang, Lingzhi, et al.
Publicado: (2018)

A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma
por: Dai, Xiaoyun, et al.
Publicado: (2017)

BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential
por: Miah, S., et al.
Publicado: (2019)

Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro
por: Burmi, Rajpal S., et al.
Publicado: (2022)

Different treatment efficacies and side effects of cytotoxic chemotherapy
por: Li, Low-Jia, et al.
Publicado: (2020)

Clinical translation of patient-derived tumour organoids- bottlenecks and strategies
por: Foo, Malia Alexandra, et al.
Publicado: (2022)

Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development
por: Wang, Lingzhi, et al.
Publicado: (2016)

MicroRNA-196a promotes renal cancer cell migration and invasion by targeting BRAM1 to regulate SMAD and MAPK signaling pathways
por: Cui, Jianzhou, et al.
Publicado: (2021)

PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression
por: Deng, Shuo, et al.
Publicado: (2022)

Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK
por: Lofgren, Kristopher A, et al.
Publicado: (2011)

Annexin-A1 Regulates MicroRNA-26b* and MicroRNA-562 to Directly Target NF-κB and Angiogenesis in Breast Cancer Cells
por: Anbalagan, Durkeshwari, et al.
Publicado: (2014)

Methyl-Thiol-Bridged Oxadiazole and Triazole Heterocycles as Inhibitors of NF-κB in Chronic Myelogenous Leukemia Cells
por: Basappa, Basappa, et al.
Publicado: (2023)

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
por: Ma, Zhaowu, et al.
Publicado: (2021)

Structure of the BRK domain of the SWI/SNF chromatin remodeling complex subunit BRG1 reveals a potential role in protein–protein interactions
por: Allen, Mark D., et al.
Publicado: (2020)

Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis
por: Sim, Wilson, et al.
Publicado: (2021)

Robust delivery of RIG‐I agonists using extracellular vesicles for anti‐cancer immunotherapy
por: Peng, Boya, et al.
Publicado: (2022)

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1
por: Wang, Lingzhi, et al.
Publicado: (2017)

Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway
por: Wang, Tingting, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hs3jliinljv3b57ljch2m1djdt